Goldman Sachs’s Vigil Neuroscience VIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-42,562
| Closed | -$338K | – | 6668 |
|
|
2025
Q2 | $338K | Sell |
42,562
-13,004
| -23% | -$58.3K | ﹤0.01% | 5377 |
|
|
2025
Q1 | $98.9K | Sell |
55,566
-201,076
| -78% | -$451K | ﹤0.01% | 5786 |
|
|
2024
Q4 | $436K | Buy |
+256,642
| New | +$758K | ﹤0.01% | 5326 |
|
|
2024
Q3 | – | Sell |
-401,139
| Closed | -$1.6M | – | 6087 |
|
|
2024
Q2 | $1.6M | Buy |
401,139
+382,900
| +2,099% | +$1.31M | ﹤0.01% | 4083 |
|
|
2024
Q1 | $62.2K | Sell |
18,239
-66,861
| -79% | -$209K | ﹤0.01% | 5301 |
|
|
2023
Q4 | $288K | Sell |
85,100
-61,102
| -42% | -$314K | ﹤0.01% | 5027 |
|
|
2023
Q3 | $788K | Buy |
146,202
+133,194
| +1,024% | +$920K | ﹤0.01% | 4411 |
|
|
2023
Q2 | $122K | Sell |
13,008
-11,818
| -48% | -$112K | ﹤0.01% | 5323 |
|
|
2023
Q1 | $243K | Sell |
24,826
-48,185
| -66% | -$542K | ﹤0.01% | 5216 |
|
|
2022
Q4 | $913K | Sell |
73,011
-13
| -0% | -$160 | ﹤0.01% | 4478 |
|
|
2022
Q3 | $665K | Sell |
73,024
-53
| -0.1% | -$389 | ﹤0.01% | 4787 |
|
|
2022
Q2 | $189K | Sell |
73,077
-762
| -1% | -$3.01K | ﹤0.01% | 5664 |
|
|
2022
Q1 | $519K | Buy |
+73,839
| New | +$974K | ﹤0.01% | 5293 |
|
Other funds holding VIGL
Goldman Sachs's VIGL Position: Q3 2025 in Review
Goldman Sachs sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 42,562 shares — an estimated $338K sold.
Goldman Sachs first reported a position in VIGL in Q1 2022 and held it in 13 quarters. The position peaked at $1.6M in Q2 2024. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.
- Goldman Sachs reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
- Goldman Sachs sold 42,562 Vigil Neuroscience shares in Q3 2025, an estimated $338K.
- Goldman Sachs first reported a position in Vigil Neuroscience in Q1 2022 and held it in 13 quarters.
- Goldman Sachs's Vigil Neuroscience position peaked at $1.6M in Q2 2024.
- 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.
Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.